OTC · Biotechnology

Carisma Therapeutics, Inc. (CARM) Stock

$0.01 -5.17% OTC: CARM Healthcare

Carisma Therapeutics, Inc., a biotechnology company, focuses on developing transformative therapies to treat liver fibrosis and cancer in the United States. Its product candidates include CT-2401, which is in preclinical trial for the treatment of liver fibrosis.

Valuation

MetricValue
Price$0.01
Market Cap$230148
P/E Ratio0.01
P/B Ratio-0.27
P/S Ratio0.01
EPS (TTM)$1.00
52-Week High$0.56
52-Week Low$0.00
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-92.22%
ROA391.78%
ROCE-442.86%
Gross Margin99.27%
Operating Margin58.60%
Net Margin52.42%
Debt/Equity-0.88
Current Ratio0.86

Annual Financials (USD)

Metric20202021202220232024
Revenue$11.0M$27.0M$10.0M$15.0M$20.0M
Operating Profit$-28.0M$-28.0M$-56.0M$-89.0M$-62.0M
Net Profit$-28.0M$0$-61.0M$-87.0M$-60.0M
EPS$-3.81$-0.04$-1.52$-2.59$-1.46
Op Margin-252.6%-106.1%-571.1%-594.8%-316.7%

Balance Sheet (USD)

Metric20202021202220232024
Total Assets$188.0M$313.0M$72.0M$90.0M$30.0M
Total Liabilities$198.0M$141.0M$215.0M$63.0M$58.0M
Cash$55.0M$163.0M$24.0M$78.0M$18.0M
Borrowings$0$3.0M$40.0M$3.0M$2.0M

Latest News

ProKidney Appoints Kenneth Locke as Chief Technical Officer GlobeNewswire · Jun 2, 2026

Cash Flow (USD)

Metric20202021202220232024
Operating Cash Flow$-27.0M$-37.0M$-8.0M$-81.0M$-60.0M
Investing Cash Flow$-1.0M$-4.0M$-37.0M$71.0M$0
Financing Cash Flow$0$0$2.0M$33.0M$-1.0M
Net Cash Flow$45.0M$-23.0M$-138.0M$53.0M$-60.0M
Free Cash Flow$-27.0M$-39.0M$-12.0M$-82.0M$-60.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.00
EV / EBITDA-0.06
FCF Yield-6110.42%
Quick Ratio0.86
Interest Coverage0.00
Return 1Y-98.57%
Return 3Y-99.94%
Return 5Y—

Ownership

Insiders Held26.56%
Institutions Held10.79%
Institutions Float Held14.69%
Institutional HolderSharesReport Date
Merck & Co., Inc.1,473,2402026-03-31
Ascentis Independent Advisors2002026-03-31
Union Bancaire Privee, UBP SA7852026-06-30

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
APLMApollomics, Inc. $18.76 +2.99% -2.41 $20.69M 0.00%
CELUCelularity Inc. $0.75 +0.13% -0.20 $21.74M 0.00%
CNSP $5.40 +0.75% -0.14 $3.10M 0.00%
DRMA $1.10 -0.90% -0.15 $749713 0.00%
IMMX $8.55 +4.65% -9.96 $465.14M 0.00%

About Carisma Therapeutics, Inc.

Carisma Therapeutics, Inc., a biotechnology company, focuses on developing transformative therapies to treat liver fibrosis and cancer in the United States. Its product candidates include CT-2401, which is in preclinical trial for the treatment of liver fibrosis. The company also develops CT-1119, a mesothelin-targeted CAR-Monocyte that is in phase I clinical trial to treat patients with advanced mesothelin-positive solid tumors, including pancreatic cancer, ovarian cancer, lung cancer, mesothelioma, and others. In addition, it develops in vivo CAR-M cell therapy to treat solid tumors, including hepatocellular carcinoma. Carisma Therapeutics, Inc. has collaboration and license agreement with ModernaTX, Inc. to address oncology gene therapies. The company was formerly known as CARMA Therapeutics Inc. and changed its name to Carisma Therapeutics, Inc. in May 2017. Carisma Therapeutics, Inc. was founded in 2016 and is headquartered in Philadelphia, Pennsylvania.

Carisma Therapeutics, Inc. is headquartered in US.

Carisma Therapeutics, Inc. (CARM) stock trades at $0.01 with a market capitalization of $230148. The stock is valued at a price-to-earnings (P/E) ratio of 0.01, price-to-book of -0.27, price-to-sales of 0.01. Over the past 52 weeks the stock has ranged between $0.00 and $0.56, and currently trades 98.2% below its 52-week high.

On profitability, Carisma Therapeutics, Inc. generates a return on equity (ROE) of -92.22%, return on capital employed of -442.86%, an operating margin of 58.60%, a net profit margin of 52.42%.

Official website: www.carismatx.com

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksAll stock screens
Run Stock Screener Investing Guides